DALLAS, TX--(Marketwire - January 26, 2011) -
BioTech Medics, Inc., (PINKSHEETS: BMCS
) announced today that it has commenced negotiations for a $5 million U.S. licensing and marketing contract for its patented SHBAN™ Alcohol Free Hand Sanitizer. The final terms and parties to the agreement are expected to be disclosed within a month. The proposed agreement includes cash, preferred shares, future dividends and ongoing royalties.
SHBAN wholesale sales were up 103% in 2010 over 2009 sales. Emphasis for 2011 will be Internet marketing, Direct TV spots, infomercials and special events.
SHBAN is superior to alcohol hand sanitizers because it is non-flammable. Alcohol hand sanitizers are a Class I fire hazard. The alcohol gel containers are like having a jar of napalm on your desk or in your purse. Additionally, the Poison Control centers have reported over 22,000 children and adults with alcohol poisoning from ingesting alcohol gels. SHBAN is a green product made with derivatives of sea weed and sea kelp. SHBAN is non-poisonous (when used as directed); yet powerful enough to kill most germs and viruses.
SHBAN's active ingredient is FDA approved as an antiseptic as well as an antimicrobial solution. SHBAN is colorless and will not stain most materials and jewelry. SHBAN's active ingredient has been clinically proven to last four hours unless you sweat or wash it off. SHBAN is gentle on hands.
SHBAN's new marketing slogan for 2011 will be "You wouldn't think of wearing a deodorant for 30 seconds; so why are you using an alcohol hand sanitizer that only lasts 30 seconds!"
Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). In Particular, when used in the preceding discussion, the words "plan," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed. The FDA has not evaluated the SHBAN statements above. SHBAN is not intended to diagnose, treat or cure any disease.